Sanofi Reports Encouraging Early Results In Covid-19 mRNA Vaccine Candidate
28 Septiembre 2021 - 1:48AM
Noticias Dow Jones
By Ed Frankl
Sanofi said Tuesday that it recorded positive interim results
from an early study into its first mRNA-based Covid-19 vaccine
candidate.
The Phase 1/2 study showed neutralizing antibody in 91% to 100%
of study participants two weeks after a second injection, the
French pharmaceutical company said.
No safety concerns were observed and side effects were
comparable to that of other messenger RNA, or mRNA, Covid-19
vaccines, Sanofi added.
Further data from the study will presented at a later date, the
company said.
"Today, we have a promising mRNA platform, which we're taking to
the next level in development, including moving to modified mRNA,
and against other diseases, including flu," said Jean-Francois
Toussaint, global head of research and development, Sanofi
Pasteur.
The company said it is continuing to develop its separate
protein candidate vaccine in partnership with GlaxoSmithKline PLC,
which is in a Phase 3 study.
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
September 28, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
